Overview

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Status:
Active, not recruiting

Trial end date:
2023-03-30

Target enrollment:

Participant gender:

Summary

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).

Phase:

Phase 2

Details

Lead Sponsor:

Amgen